SCHEMBL4789263

SCHEMBL4789263

O=C1c2ccccc2C(=O)N1C1CCN(c2cncc(-c3ccncc3Cl)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
CNR1 P21554 3/20 0.38
IDO1 P14902 1/20 0.38
CNR2 P34972 1/20 0.37
PIM1 P11309 3/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
CCNC P24863 2/20 0.36
CDK8 P49336 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CTSS P25774 1/20 0.36
PTPN11 Q06124 1/20 0.35
CDC7 O00311 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693209 0.82 MEN1 (0.47) ADRA1DADRA1AADRA1BL3MBTL1CYP1A2
SCHEMBL4694061 0.82 CNR1 (0.45) ADRA1DADRA1AADRA1BL3MBTL1CNR1
SCHEMBL4749104 0.77 CNR1 (0.56) ADRA1DADRA1AADRA1BL3MBTL1CNR1
SCHEMBL14545114 0.76 CNR1 (0.69) CNR1CNR2PTPN11
SCHEMBL3439989 0.71 L3MBTL1 (0.47) ADRA1DADRA1AADRA1BL3MBTL1
SCHEMBL14545104 0.71 CNR1 (0.44) ADRA1DADRA1AADRA1BL3MBTL1CNR1
SCHEMBL3194921 0.67 ALDH1A1 (0.52) ADRA1DADRA1AADRA1BL3MBTL1CYP2C19
SCHEMBL23658231 0.65 L3MBTL1 (0.42) ADRA1DADRA1AADRA1BL3MBTL1CCNC
SCHEMBL18208163 0.65 ADRA1D (0.39) ADRA1DADRA1AADRA1BL3MBTL1CCNC
SCHEMBL3440230 0.64 L3MBTL1 (0.40) ADRA1DADRA1AADRA1BL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 ADRA1D 83/4885ADRA1A 78/4885ADRA1B 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.